Correlation of Krebs von den Lungen-6 and fibronectin with pulmonary fibrosis in coronavirus disease 2019

被引:32
|
作者
Peng, Ding-Hui [1 ]
Luo, Yi [1 ]
Huang, Li-Jun [2 ]
Liao, Fan-Lu [1 ]
Liu, Yan-Yuan [1 ]
Tang, Peng [1 ]
Hu, Han-Ning [1 ]
Chen, Wei [1 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Lab Med, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China
[2] Huangzhou Dist Peoples Hosp, Dept Clin Lab, Huanggang, Hubei, Peoples R China
关键词
Coronavirus Disease 2019; Krebs von den Lungen-6; Pulmonary fibrosis; Fibronectin; SARS-CoV-2; INFLAMMATION;
D O I
10.1016/j.cca.2021.02.012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Objective: Coronavirus Disease 2019 (COVID-19) caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still spreading worldwide, which may progress to pulmonary fibrosis (PF), leading to the worsen outcome. As the markers of lung injury, the correlation of Krebs von den Lungen-6 (KL-6) and fibronectin (Fn) with pulmonary fibrosis in COVID-19 was still unclear. Methods: 113 patients diagnosed as COVID-19 were enrolled in this retrospective study, and divided into three categories as mild, moderate and severe cases. The concentrations of serum KL-6 and Fn at hospital admission were tested using the method of latex agglutination assay and immunoturbidimetic assay, respectively. Results: Compared with that in the non-severe COVID-19 cases and normal control subjects, serum KL-6 concentration on admission was significantly higher in the severe group, which was positively correlated with Creactive protein, and negatively correlated with lymphocytes count. Whereas, no obvious elevation in serum Fn concentration was investigated in COVID-19 patients with the different phenotypes. The severe cases displayed the higher incident rate of pulmonary fibrosis at hospital discharge. Compared with non-PF patients, the COVID19 cases with PF had the higher serum KL-6 values. Conclusion: Serum KL-6 concentration was significantly elevated in severe COVID-19 patients, which may be useful for evaluating the disease severity. For early prevention of the development of pulmonary fibrosis, high concentrations of serum KL-6 in the early stage of COVID-19 should be paid close attention.
引用
收藏
页码:48 / 53
页数:6
相关论文
共 15 条
  • [1] Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease
    Benyamine, Audrey
    Heim, Xavier
    Resseguier, Noemie
    Bertin, Daniel
    Gomez, Carine
    Ebbo, Mikael
    Harle, Jean-Robert
    Kaplanski, Gilles
    Rossi, Pascal
    Bardin, Nathalie
    Granel, Brigitte
    RHEUMATOLOGY INTERNATIONAL, 2018, 38 (05) : 813 - 819
  • [2] Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: A systematic review and meta-analysis
    Wang, Chuanzhu
    Wang, Qingbao
    Liu, Tong
    Zhu, Jun
    Zhang, Boke
    CLINICAL BIOCHEMISTRY, 2023, 114 : 30 - 38
  • [3] Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis
    Mostafa, Amira Ismail
    Salem, Ayman Elsayed
    Ahmed, Heba Allah Moussa
    Bayoumi, Aml Ibrahim
    Halim, Radwa M. Abdel
    Samie, Rasha M. Abdel
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2021, 84 (03) : 200 - 208
  • [4] Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients
    Xue, Mingshan
    Zhang, Teng
    Chen, Hao
    Zeng, Yifeng
    Lin, Runpei
    Zhen, Yingjie
    Li, Ning
    Huang, Zhifeng
    Hu, Haisheng
    Zhou, Luqian
    Wang, Hui
    Zhang, Xiaohua Douglas
    Sun, Baoqing
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2021, 17 (06): : 1565 - 1573
  • [5] Idiopathic Pleuroparenchymal Fibroelastosis is Characterized by an Elevated Serum Level of Surfactant Protein-D, but Not Krebs Von Den Lungen-6
    Sato, Seidai
    Hanibuchi, Masaki
    Fukuya, Asami
    Yabuki, Youhei
    Bando, Hiroki
    Yoshijima, Terumi
    Goto, Hisatsugu
    Ogawa, Hirohisa
    Nishioka, Yasuhiko
    LUNG, 2014, 192 (05) : 711 - 717
  • [6] Serum Krebs von den Lungen-6 is associated with in-Hospital mortality of patients with severe Community-Acquired Pneumonia: A retrospective cohort study
    Lu, Rongli
    Yang, Hang
    Peng, Wenzhong
    Tang, Haiyun
    Li, Yi
    Lin, Fengyu
    Zhou, Aiyuan
    Pan, Pinhua
    CLINICA CHIMICA ACTA, 2023, 548
  • [7] Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases A meta-analysis
    Zhong, Danli
    Wu, Chanyuan
    Bai, Jingjing
    Hu, Chaojun
    Xu, Dong
    Wang, Qian
    Zeng, Xiaofeng
    MEDICINE, 2020, 99 (16) : E19695
  • [8] Association between serum Krebs von den Lungen-6 (KL-6), Carcinoma antigen 15-3 (CA15-3), and connective tissue disease-related interstitial pneumonia (CTD-ILD)
    Guo, Zijun
    Zheng, Peiyan
    Hu, Haisheng
    Huang, Huimin
    Wei, Nili
    Luo, Wenting
    Chen, Xi
    Li, Ning
    Sun, Baoqing
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (08): : 8043 - 8053
  • [9] Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019
    Ogata, Hiroaki
    Nakagawa, Taisuke
    Sakoda, Soichiro
    Ishimatsu, Akiko
    Taguchi, Kazuhito
    Kadowaki, Masako
    Moriwaki, Atsushi
    Yoshida, Makoto
    RESPIROLOGY CASE REPORTS, 2021, 9 (05):
  • [10] Post-Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention
    Yoon, Hee-Young
    Uh, Soo-Taek
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2022, 85 (04) : 320 - 331